Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

REPL US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Replimune Group, Inc.(REPL US)

$16.06+3.0123.07%Ext:$15.70-0.362.23%(After Hours · 22:29:38 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Replimune Group, Inc. — Company Profile

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UQ
CEO
Sushil Patel
Headquarters
Woburn, MA, US
IPO Date
Jul 20, 2018
Employees
465
Website
www.replimune.com

Key Metrics

Price
$13.07
Market Cap
$1.10B
Revenue (TTM)
$0.00
Net Income (TTM)
$-70930000.00
EPS (TTM)
-0.77
P/E (TTM)
-3.49
P/B (TTM)
5.22
Dividend Yield
0.00%
ROE (TTM)
-33.69%
ROA (TTM)
-21.26%
Operating Margin
0.00%
Beta
0.90

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Website
www.replimune.com
Location
Woburn, MA, US
Phone781 222 9600
Employees465
CEOSushil Patel
Sector
Materials
Industry
Paper & Forest Products
IPO DateJul 20, 2018

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(642)

Expand
  • 144Peeples-Dyer Veleka28 Oct
  • 10-QQ2ended 30 Sept 202628 Oct
  • 8-KResults of Operations and Financial Condition28 Oct
  • 8-KAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year16 Sep
  • 4Astley-Sparke Philip24 Aug
  • 4Hill Emily Luisa19 Aug
  • S-3ASRAutomatic shelf registration statement (S-3)14 Aug
  • 10-QQ1ended 30 Jun 202614 Aug
  • SC 13G/AReplimune Group, Inc.14 Aug
  • 8-KResults of Operations and Financial Condition14 Aug
  • 4Patel Sushil12 Aug
  • 4Hill Emily Luisa12 Aug
  • 4Xynos Konstantinos12 Aug
  • 4Schwendenman Andrew12 Aug
  • SC 13D/AReplimune Group, Inc.11 Aug
  • 4Statement of changes in beneficial ownership11 Aug
  • SC 13GReplimune Group, Inc.10 Aug
  • 8-K/AOther Events10 Aug
  • 8-KOther Events10 Aug
  • 424B5Prospectus filing (Rule 424(b)(5))10 Aug

News

  • Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript28 Oct
  • Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update28 Oct
  • Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 202622 Oct
  • Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL5 Oct
  • Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm5 Oct
  • REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th2 Oct
  • Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma1 Oct
  • Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm1 Oct
  • SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL1 Oct
  • INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL1 Oct
  • REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky30 Sep
  • REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th29 Sep
  • INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL29 Sep
  • REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact SueWallSt29 Sep
  • Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors29 Sep
  • Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP128 Sep
  • Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm28 Sep
  • REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact Levi & Korsinsky28 Sep
  • INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL24 Sep
  • Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm24 Sep

Mentions in Filings

  • … ion committee approved the following peer group set forth below and used this peer group to inform compensation decisions for 2025: Alector, Inc. Erasca(1) Relay Therapeutics AnaptysBio, Inc. IGM Biosciences, Inc. <strong>Replimune Group, Inc.</strong> Arcus Biosciences(1) Immunome(1) Sutro Biopharma, Inc. Bicycle Therapeutics Iteos Therapeutics Syndax Pharmaceuticals(1) C4 Therapeutics Kura Oncology, Inc. Xencor Cogent Biosciences MacroGenics, Inc. Cullinan Ther …
    Zymeworks Inc.Replimune Group, Inc.·ARS - Annual report to security holders·FY25·26 Oct
  • … directors of Kronos Bio, Inc. (Nasdaq: KRON) from May 2018 to March 2023, Omega Alpha SPAC (Nasdaq: OMEG) from October 2020 to December 2022, Ikena Oncology Inc. (Nasdaq: IKNA) from December 2020 to July 2025, and <strong>Replimune Group, Inc.</strong> (Nasdaq: REPL) from May 2015 to January 2022. Dr. Stampacchia has a Ph.D. in Molecular Biology from the University of Geneva, a Doctorate in Biotechnology from European Union Strasbourg, and an MSc in Genetics from …
    WINDWARD BIO GROUP AGReplimune Group, Inc.·F-1 - Registration statement (foreign issuer)·Q4 26·23 Oct
  • … directors of Kronos Bio, Inc. (Nasdaq: KRON) from May 2018 to March 2023, Omega Alpha SPAC (Nasdaq: OMEG) from October 2020 to December 2022, Ikena Oncology Inc. (Nasdaq: IKNA) from December 2020 to July 2025, and <strong>Replimune Group, Inc.</strong> (Nasdaq: REPL) from May 2015 to January 2022. Dr. Stampacchia has a Ph.D. in Molecular Biology from the University of Geneva, a Doctorate in Biotechnology from European Union Strasbourg, and an MSc in Genetics from …
    WINDWARD BIO GROUP AGReplimune Group, Inc.·DRS/A - Draft registration statement (amendment)·Q4 26·13 Oct
  • … directors of Kronos Bio, Inc. (Nasdaq: KRON) from May 2018 to March 2023, Omega Alpha SPAC (Nasdaq: OMEG) from October 2020 to December 2022, Ikena Oncology Inc. (Nasdaq: IKNA) from December 2020 to July 2025, and <strong>Replimune Group, Inc.</strong> (Nasdaq: REPL) from May 2015 to January 2022. Dr. Stampacchia has a Ph.D. in Molecular Biology from the University of Geneva, a Doctorate in Biotechnology from European Union Strasbourg, and an MSc in Genetics from …
    WINDWARD BIO GROUP AGReplimune Group, Inc.·DRS/A - Draft registration statement (amendment)·Q3 26·21 Sep
  • … developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. We may compete with other cell therapy or immunotherapy companies such as Iovance Biotherapeutics Inc., <strong>Replimune Group</strong> Inc., AbelZeta Inc., Biosyngen Pte Ltd, GRIT Biotechnology Co., Ltd., Shanghai Juncell Therapeutics Co., Ltd., Immatics N.V., Immunocore Holdings plc, Intima Bioscience, Inc., KSQ Therapeutics, Inc., Marker Therapeuti …
    Obsidian Therapeutics, Inc.Replimune Group, Inc.·S-1 - Registration statement (general form)·Q3 26·28 Aug
  • … directors of Kronos Bio, Inc. (Nasdaq: KRON) from May 2018 to March 2023, Omega Alpha SPAC (Nasdaq: OMEG) from October 2020 to December 2022, Ikena Oncology Inc. (Nasdaq: IKNA) from December 2020 to July 2025, and <strong>Replimune Group, Inc.</strong> (Nasdaq: REPL) from May 2015 to January 2022. Dr. Stampacchia has a Ph.D. in Molecular Biology from the University of Geneva, a Doctorate in Biotechnology from European Union Strasbourg, and an MSc in Genetics from …
    WINDWARD BIO GROUP AGReplimune Group, Inc.·DRS/A - Draft registration statement (amendment)·Q3 26·27 Aug

Key Stats

Trading

Px/Chg 1D$13.07 / -2.83%
Avg Volume5.88M
Beta0.90
Mkt Cap1.10B
FD Mkt Cap1.28B

Float

Shrs Out/Float84.03M / 78.73M
Short Float0.31%
Days to Cover6.37
Stock Repurchased$0.00

Current Valuation

EV1.05B
EV/EBITDA-3.38
EV/Sales0.00
P/B5.22
P/S0.00
FCF Yield-6.02%
ROE-33.69%
ROA-21.26%
Current Ratio5.60

Estimates

P/E-3.49
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgAug '22Aug '23Aug '24Aug '25Oct '26
PRICE-BASED RATIOS
Price / Earnings-8.10-9.06-7.12-2.84-5.98-15.48
Price / Sales0.000.000.000.000.000.00
Price / Book Value2.552.602.241.641.075.22
Price / Free Cash Flow-10.02-12.66-9.52-3.20-8.08-16.62
ENTERPRISE VALUE METRICS
Enterprise Value845.1996.71,155.3613.9408.11,051.6
Enterprise Value / Sales0.000.000.000.000.000.00
Enterprise Value / EBITDA-7.86-8.71-6.73-2.70-5.67-15.48
Enterprise Value / EBIT-7.67-8.38-6.63-2.64-5.61-15.11

Financials

Full Financials
Millions USD5Yr CAGR (%)Mar '21Mar '22Mar '23Mar '24Mar '25
INCOME STATEMENT
Revenue—-----
Gross Income—-4.1-4.6---
EBITDA35%-76.5-114.4-171.7-227.8-253.9
EBIT34%-80.6-119.0-174.2-232.9-259.9
Net Income32.2%-80.9-118.0-174.3-215.8-247.3
EPS (Diluted)15.1%-1.75-2.26-2.99-3.24-3.07
BALANCE SHEET
Cash & ST Inv39.1%476.3395.7583.4420.7483.8
Total Assets37.7%543.1461.2646.6487.7551.3
Total Liabilities32.2%44.450.091.3113.2135.5
Total Shareholder Equity-4.4%498.7411.2555.3374.5415.8
CASH FLOW
Net Operating Cash Flow33%-61.4-82.2-128.1-185.5-192.3
Cap Ex29.3%-2.4-2.3-2.3-5.7-6.7
Free Cash Flow32.9%-63.8-84.5-130.3-191.1-198.9

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)11.57
Basic Shares84.03
Market Cap972.1
Diluted Shares105.18
Fully Diluted Shares Outstanding105.18
Fully Diluted Market Cap1,216.8
+Consolidated Debt-
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-307.8
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value664.3

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US